Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
The Nifty Pharma index surged 2% to a fresh 52-week high of 25,445.85 on June 29, 2026, with Dr. Reddy's, Cipla, Sun Pharma, and Lupin leading gains, backed by six months of double-digit IPM growth and GLP-1 capacity expansion.
Pharmaceutical stocks extended their rally on June 29, 2026, with the Nifty Pharma index surging 2% to a fresh 52-week high of 25,463.70, significantly outperforming the broader market, where the Nifty 50 slipped 0.20% to 24,014. The sector has also outperformed over the past week, with the Nifty Pharma index gaining 2.08% compared with a 0.18% rise in the Nifty 50.
Among individual stocks, Dr. Reddy’s Laboratories marked its 52-week high with an increase of 4%, whereas Sun Pharmaceutical Industries share price climbed up by 1.5% to hover near its 52-week high. The Cipla and Lupin share price also recorded an upward move of 3% and 2%, respectively.
As per Indian Pharma Post, Indian Pharmaceutical Market growth improved to 10.7% in MAT May 2026, supported by a well-balanced mix of volume growth of 3.2%, price growth of 4.5%, and new product introductions of 3%. All three growth levers improved simultaneously, pointing to broad-based market expansion. May 2026 marked the sixth consecutive month of YoY growth exceeding 10% for the Indian Pharmaceutical Market. Nine out of ten key therapy categories grew by more than 10%, and the anti-diabetic segment alone rose 14.5%, driven partly by GLP-1 drugs.
Note: MAT stands for Moving Annual Total for the 12-month period
One of the more prominent near-term drivers is the rapid expansion of the GLP-1 drug segment. As per Business Standard, India's CDMOs are rapidly expanding capacity to meet soaring demand for GLP-1 drugs such as semaglutide, following the expiry of semaglutide patents in several markets, which triggered a rush by generic drugmakers to secure manufacturing partners. With semaglutide's patent expiry in March 2026, seven to ten branded generics are likely to enter the market in FY27, driving large-volume expansion.
The global move to diversify pharmaceutical supply chains away from Chinese API and CDMO suppliers has been building for some time. What has changed recently is that it is now showing up in actual revenue. India is strengthening its position as a China+1 hub as global biopharma outsourcing accelerates, supported by strong compliance, competitive cost structures, and growing investments in advanced modalities such as biologics.
Increasing opportunities in speciality drugs, CDMOs, biosimilars, and complex generics are strengthening investor confidence, and the market is beginning to recognise that Indian pharma is gradually moving beyond a pure generics story toward innovation-led growth.
After prolonged pressure on pricing in the US generics market, conditions have largely normalised. This matters because the United States remains the single largest export destination for Indian pharmaceutical companies. The stabilisation removes one of the more persistent overhangs the sector has carried for several years.
Additionally, the USFDA approached Indian pharmaceutical manufacturers through the Indian Drug Manufacturers' Association to help address a domestic shortage of ifosfamide, a generic chemotherapy drug used in treating testicular, bladder, and lung cancer, underscoring the continued reliance on Indian manufacturing within regulated markets.
Source: Dalal Street Investment Journal, NSE India, IDMA, Business Standard, IPP
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading